헬스케어 외관 검사 서비스 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 기술별, 최종 용도별, 지역별 및 부문 예측(2026-2033년)

Healthcare Visual Inspection Services Market Summary

The global healthcare visual inspection services market size was valued at USD 4.4 billion in 2025 and is projected to grow from USD 4.8 billion in 2026 to USD 9.5 billion by 2033, at a CAGR of 10.1% from 2026 to 2033. North America dominated the market, accounting for the largest share of 40.6% in 2025

The healthcare visual inspection services industry is anticipated to grow over the forecast period owing to the increasing production of sterile injectable drugs and biologics, rising regulatory focus on product quality and particulate control, growing adoption of automated and semi-automated visual inspection technologies, increasing outsourcing of inspection activities to CDMOs and specialized service providers, and expanding pharmaceutical manufacturing capacity worldwide. The market growth is further supported by the increasing commercialization of complex biologics, prefilled syringes, cartridges, and combination products that require stringent inspection throughout the manufacturing process. The need to reduce product recalls, improve batch release efficiency, and maintain compliance with global GMP requirements continues to increase demand for specialized healthcare visual inspection services.

The growing production of sterile injectable medicines remains a major driver of market growth. Injectable biologics, vaccines, ophthalmic products, and other parenteral formulations require 100% visual inspection to detect particulate contamination, cosmetic defects, variations in fill volume, and issues with container closure integrity before commercial release. The increasing complexity of injectable drug products has prompted pharmaceutical manufacturers to adopt automated inspection technologies to improve inspection consistency and support regulatory compliance. For instance, in February 2025, the Parenteral Drug Association announced that its 2025 Visual Inspection Forum would focus on evolving regulatory expectations, automated visual inspection technologies, artificial intelligence integration, and updated GMP requirements for injectable medicines, highlighting the growing industry focus on advanced inspection capabilities.

The increasing outsourcing of pharmaceutical manufacturing is further supporting demand for healthcare visual inspection services. Pharmaceutical and biotechnology companies continue to partner with CDMOs that offer integrated fill-and-finish, packaging, and visual inspection capabilities to reduce capital investment, improve operational efficiency, and accelerate product commercialization. The expansion of biologics manufacturing and high-value injectable products has increased demand for service providers equipped with validated manual, semi-automated, and automated inspection systems. Furthermore, technological advances in machine vision, digital imaging, and artificial intelligence are improving defect-detection accuracy while increasing inspection throughput. These developments are enabling service providers to expand inspection capacity for commercial-scale pharmaceutical manufacturing and meet increasingly stringent global quality standards.

Moreover, the high capital investment required for advanced automated inspection systems, complex validation requirements, and the need for highly trained personnel to maintain regulatory compliance contribute to the market. The increasing adoption of artificial intelligence-enabled inspection platforms, continued expansion of biologics and injectable drug manufacturing, and rising outsourcing by pharmaceutical companies are expected to create significant long-term opportunities for healthcare visual inspection service providers. Overall, the market is expected to witness steady growth as pharmaceutical manufacturers continue to prioritize product quality, patient safety, regulatory compliance, and efficient inspection processes across global manufacturing operations.

Global Healthcare Visual Inspection Services Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global healthcare visual inspection services market report based on product, technology, end-use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical
• Medical Device
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Manual Visual Inspection (MVI)
• Semi-Automated Visual Inspection (SAVI)
• Automated Visual Inspection (AVI)
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceutical & Biopharmaceutical Companies
• Medical Device Companies
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Technology
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Healthcare Visual Inspection Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Force Analysis
  • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Healthcare Visual Inspection Services Market: Product Estimates & Trend Analysis

• 4.1. Healthcare Visual Inspection Services Market, By Product: Segment Dashboard
• 4.2. Healthcare Visual Inspection Services Market, By Product: Movement Analysis
• 4.3. Healthcare Visual Inspection Services Market Estimates & Forecasts, By Product, 2021 - 2033 (USD Million)
• 4.4. Pharmaceutical
  • 4.4.1. Pharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Medical Device
  • 4.5.1. Medical Device Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Healthcare Visual Inspection Services Market: Technology Estimates & Trend Analysis

• 5.1. Healthcare Visual Inspection Services Market, By Technology: Segment Dashboard
• 5.2. Healthcare Visual Inspection Services Market, By Technology: Movement Analysis
• 5.3. Healthcare Visual Inspection Services Market Estimates & Forecasts, By Technology, 2021 - 2033 (USD Million)
• 5.4. Manual Visual Inspection (MVI)
  • 5.4.1. Manual Visual Inspection (MVI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Semi-Automated Visual Inspection (SAVI)
  • 5.5.1. Semi-Automated Visual Inspection (SAVI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Automated Visual Inspection (AVI)
  • 5.6.1. Automated Visual Inspection (AVI) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Healthcare Visual Inspection Services Market: End Use Estimates & Trend Analysis

• 6.1. Healthcare Visual Inspection Services Market, By End Use: Segment Dashboard
• 6.2. Healthcare Visual Inspection Services Market, By End Use: Movement Analysis
• 6.3. Healthcare Visual Inspection Services Market Estimates & Forecasts, By Drug Type, 2021 - 2033 (USD Million)
• 6.4. Pharmaceutical & Biopharmaceutical Companies
  • 6.4.1. Pharmaceutical & Biopharmaceutical Companies Market, 2021 - 2033, (USD Million)
• 6.5. Medical Device Companies
  • 6.5.1. Medical Device Companies Market, 2021 - 2033, (USD Million)
• 6.6. Others
  • 6.6.1. Others Market, 2021 - 2033, (USD Million)

Chapter 7. Healthcare Visual Inspection Services Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Dashboard
• 7.2. Regional Market Share Analysis, 2025 & 2033
• 7.3. North America
  • 7.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.2. U.S.
    • 7.3.2.1. Key Country Dynamics
    • 7.3.2.2. Competitive Scenario
    • 7.3.2.3. Regulatory Framework
    • 7.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.3. Canada
    • 7.3.3.1. Key Country Dynamics
    • 7.3.3.2. Competitive Scenario
    • 7.3.3.3. Regulatory Framework
    • 7.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.3.4. Mexico
    • 7.3.4.1. Key Country Dynamics
    • 7.3.4.2. Competitive Scenario
    • 7.3.4.3. Regulatory Framework
    • 7.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.4. Europe
  • 7.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.2. UK
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.3. Germany
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.4. France
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.5. Italy
    • 7.4.5.1. Key Country Dynamics
    • 7.4.5.2. Competitive Scenario
    • 7.4.5.3. Regulatory Framework
    • 7.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.6. Spain
    • 7.4.6.1. Key Country Dynamics
    • 7.4.6.2. Competitive Scenario
    • 7.4.6.3. Regulatory Framework
    • 7.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.7. Denmark
    • 7.4.7.1. Key Country Dynamics
    • 7.4.7.2. Competitive Scenario
    • 7.4.7.3. Regulatory Framework
    • 7.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.8. Sweden
    • 7.4.8.1. Key Country Dynamics
    • 7.4.8.2. Competitive Scenario
    • 7.4.8.3. Regulatory Framework
    • 7.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.4.9. Norway
    • 7.4.9.1. Key Country Dynamics
    • 7.4.9.2. Competitive Scenario
    • 7.4.9.3. Regulatory Framework
    • 7.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.2. Japan
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.3. China
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.4. India
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.5. Australia
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5.7. South Korea
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Latin America
  • 7.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.2. Brazil
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6.3. Argentina
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. MEA
  • 7.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.2. South Africa
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.4. Saudi Arabia
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Framework
    • 7.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.5. Kuwait
    • 7.7.5.1. Key Country Dynamics
    • 7.7.5.2. Competitive Scenario
    • 7.7.5.3. Regulatory Framework
    • 7.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.6. Qatar
    • 7.7.6.1. Key Country Dynamics
    • 7.7.6.2. Competitive Scenario
    • 7.7.6.3. Regulatory Framework
    • 7.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7.7. Oman
    • 7.7.7.1. Key Country Dynamics
    • 7.7.7.2. Competitive Scenario
    • 7.7.7.3. Regulatory Framework
    • 7.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Key Participant Categorization
  • 8.1.1. Market Leaders
  • 8.1.2. Emerging Players
• 8.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 8.3. Company Profiles
  • 8.3.1. Charles River Laboratories
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. Jabil Inc.
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Lonza Group
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Grand River Aseptic Manufacturing
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. Vetter Pharma
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. NIVAGEN
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Recipharm AB
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Samsung Biologics
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. SGS SA
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. West Pharmaceutical Services, Inc.
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. Adragos Pharma
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives